- Trials with a EudraCT protocol (560)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
560 result(s) found for: ELISA.
Displaying page 1 of 28.
EudraCT Number: 2018-003068-29 | Sponsor Protocol Number: P170934J | Start Date*: 2018-11-07 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: Evaluation of immunological response following a revaccination with PPS23 boosted or not by PCV13 in splenectomised patients (SPLENEVAC-2) | |||||||||||||
Medical condition: Asplenic patients at risk for invasive pneumococcal diseases | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-001419-64 | Sponsor Protocol Number: NOR-107 | Start Date*: 2014-01-24 | |||||||||||
Sponsor Name:Takeda Vaccines (Montana), Inc. | |||||||||||||
Full Title: A Phase II, Randomized, Controlled, Double-Blind, Dosage and Adjuvant Justification, Safety and Immunogenicity Trial of Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine Adjuv... | |||||||||||||
Medical condition: Prevention of gastroenteritis caused by norovirus | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-002584-63 | Sponsor Protocol Number: VAC31518COV2001 | Start Date*: 2020-09-02 | |||||||||||
Sponsor Name:Janssen Vaccines & Prevention B.V. | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled Phase 2a Study to Evaluate a Range of Dose Levels and Vaccination Intervals of Ad26.COV2.S in Healthy Adults Aged 18 to 55 Years Inclusive and Adults ... | |||||||||||||
Medical condition: Healthy Volunteers (Prevention of COVID-19) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) NL (Completed) ES (Restarted) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-000767-26 | Sponsor Protocol Number: 700401 | Start Date*: 2005-05-09 |
Sponsor Name:Baxter AG | ||
Full Title: Open-label follow-up study to investigate the seropersistence of TBE antibodies and the booster response to a tick-borne encephalitis vaccine in children and adolescents aged 3 - 18 years. | ||
Medical condition: Tick-borne encephalitis | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: AT (Completed) DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-011357-41 | Sponsor Protocol Number: 112772 | Start Date*: 2009-07-01 | |||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | |||||||||||||
Full Title: A long-term, open, follow-up of the immunogenicity and safety of GlaxoSmithKline Biologicals’ HPV-16/18 L1 VLP AS04 vaccine in healthy female subjects up to 10 years after administration of the fir... | |||||||||||||
Medical condition: For active immunization of women from the age of 10 years onwards to prevent cervical cancer (squamous-cell carcinoma and adenocarcinoma) by protecting against incident and persistent infections, c... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-000768-19 | Sponsor Protocol Number: 700501 | Start Date*: 2005-08-02 |
Sponsor Name:Baxter Vaccine AG | ||
Full Title: Multicenter Phase IV Study to Investigate the Seropersistence of TBE Virus Antibodies Approximately 3 Years after a Booster Vaccination with FSME-IMMUN 0.25 ml Junior in Children | ||
Medical condition: Tick-borne encephalitis | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-000369-44 | Sponsor Protocol Number: 111375 | Start Date*: 2009-03-24 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A long-term, open follow-up of the immunogenicity and safety of GlaxoSmithKline Biologicals’ HPV-16/18 VLP/AS04 vaccine in healthy female subjects up to 10 years after administration of the first v... | ||
Medical condition: For the prevention of high-grade cervical intraepithelial neoplasia (CIN grades 2 and 3) and cervical cancer causally related to human papillomavirus (HPV) types 16 and 18. | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-003941-24 | Sponsor Protocol Number: Td528 | Start Date*: 2016-01-13 | |||||||||||||||||||||
Sponsor Name:SANOFI PASTEUR SA | |||||||||||||||||||||||
Full Title: Immunogenicity and Safety of Sanofi Pasteur’s Tdap Combined Vaccine (ADACEL) as a Booster Dose, versus Local DT Vaccine in Healthy Children or versus Local Td Vaccine in Healthy Adolescents and Adu... | |||||||||||||||||||||||
Medical condition: Active immunization against tetanus, diphtheria and pertussis | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Children, Under 18, Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-001584-20 | Sponsor Protocol Number: 207543 | Start Date*: 2017-10-02 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A Phase I/II, randomized, controlled, observer-blind, multi-center study to assess the reactogenicity, safety and immunogenicity of three GlaxoSmithKline (GSK) Biologicals’ investigational supra-se... | ||
Medical condition: Healthy volunteers (active immunization for the prevention of disease caused by influenza virus) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-000255-50 | Sponsor Protocol Number: 207347 | Start Date*: 2018-03-12 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A phase III, open-label, mono-centre, follow-up extension study to evaluate the persistence of immune response to GSK Biologicals’ HPV vaccine in healthy Chinese female subjects who received three ... | ||
Medical condition: Healthy volunteers (to evaluate the persistence of immune response in subjects who received the HPV-16/18 vaccine, seven to eight years after the last dose of vaccination in the primary study) | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2018-003379-37 | Sponsor Protocol Number: VLA15-201 | Start Date*: 2019-05-20 | |||||||||||||||||||||
Sponsor Name:Valneva Austria GmbH | |||||||||||||||||||||||
Full Title: IMMUNOGENICITY AND SAFETY STUDY OF VLA15, A MULTIVALENT RECOMBINANT OSPA BASED VACCINE CANDIDATE AGAINST LYME BORRELIOSIS, IN HEALTHY ADULTS AGED 18 TO 65 YEARS - A RANDOMIZED, CONTROLLED, OBSERVER... | |||||||||||||||||||||||
Medical condition: Prevention against Lyme borreliosis | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Completed) BE (Completed) AT (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-000778-20 | Sponsor Protocol Number: NOR-202 | Start Date*: 2014-07-04 | |||||||||||
Sponsor Name:Takeda Vaccines, Inc. | |||||||||||||
Full Title: A Phase II, Randomized, Double-Blind, Dosage, Safety and Immunogenicity Trial of Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine combined with Aluminum Hydroxide adjuvant in... | |||||||||||||
Medical condition: Prevention of gastroenteritis caused by norovirus | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-001325-14 | Sponsor Protocol Number: 580299/008 | Start Date*: 2004-08-12 |
Sponsor Name:GlaxoSmithKline SA | ||
Full Title: Estudio en fase III, doble ciego, aleatorizado, controlado, multicéntrico para evaluar la eficacia de la vacuna HPV-16/18 VLP/AS04 de GlaxoSmithKline Biologicals comparada con la vacuna antihepatit... | ||
Medical condition: cervical cancer => study is conducted in healthy female | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Female | |
Trial protocol: ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-005354-35 | Sponsor Protocol Number: E2I43 | Start Date*: 2015-12-04 | ||||||||||||||||||||||||||
Sponsor Name:SANOFI PASTEUR INTERNATIONAL | ||||||||||||||||||||||||||||
Full Title: Immunogenicity and Safety of the Aventis Pasteur DTacP-IPV//PRP~T Combined Vaccine (PENTAXIM™), Given as a Three-Dose Primary Vaccination at 6, 10, and 14 Weeks of Age and Followed by a Booster Dos... | ||||||||||||||||||||||||||||
Medical condition: Healty volunteers: active immunization against diphtheria, tetanus, pertussis, poliomyelitis and invasive infections caused by Haemophilus influenzae type b (such as meningitis, septicaemia, cellul... | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: Outside EU/EEA | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-005801-14 | Sponsor Protocol Number: VAC31518COV3003 | Start Date*: 2021-02-15 | |||||||||||
Sponsor Name:Janssen Vaccines & Prevention B.V. | |||||||||||||
Full Title: A Randomized, Double-blind, Phase 3 Study to Evaluate 6 Dose Levels of Ad26.COV2.S Administered As a Two-Dose Schedule in Healthy Adults | |||||||||||||
Medical condition: Healthy Volunteers (Prevention of SARS-CoV-2-mediated COVID-19) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-003094-15 | Sponsor Protocol Number: V98_06E1 | Start Date*: 2016-02-11 | |||||||||||
Sponsor Name:GlaxoSmithKline Biologicals S.A. | |||||||||||||
Full Title: A Phase 2, Non-Randomized, Controlled, Open-Label, Parallel-Group, Extension Study to Evaluate the Immunogenicity and Safety of the Second Dose of GBS Trivalent Vaccine in Healthy Non-pregnant Subj... | |||||||||||||
Medical condition: Healthy person immune response to a second dose of Group B Streptococcus polysaccharide capsule antigens | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-003610-15 | Sponsor Protocol Number: RITUXVAS | Start Date*: 2005-12-15 |
Sponsor Name:Cambridge University Hospitals NHS Foundation Trust | ||
Full Title: An international, randomised, open trial comparing a rituximab based regimen with a standard cyclophosphamide/azathioprine regimen in the treatment of 'generalised' ANCA associated vasculitis. | ||
Medical condition: Anti neutophil cytoplasmic antibody (ANCA) associated vasculitis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) CZ (Completed) SE (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-002872-41 | Sponsor Protocol Number: ELR100710 | Start Date*: 2005-10-18 |
Sponsor Name:GlaxoSmithKline Research & Development Limited | ||
Full Title: A Study to Validate Key Therapeutic Targets and Biomarkers during Allergen Exposure in Subjects with Allergic Rhinitis | ||
Medical condition: Seasonal allergic rhinitis | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-003310-14 | Sponsor Protocol Number: SHO20190708 | Start Date*: 2019-12-05 |
Sponsor Name:Department of Dermatology, Bispebjerg Hospital | ||
Full Title: Laser immunotherapy with and without topical anti-PD1 in basal cell carcinomas | ||
Medical condition: Basal cell carcinoma in 24-30 patients | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: DK (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-005105-20 | Sponsor Protocol Number: V48P4E3 | Start Date*: 2014-11-28 |
Sponsor Name:Novartis Vaccines and Diagnostics | ||
Full Title: A phase IV, uncontrolled, open-label, multi-center study in children and adolescents: Evaluation of long-term immunogenicity in subjects boosted with a new pediatric TBE vaccine (free of protein-de... | ||
Medical condition: Prophylaxis: Tick-borne-encephalitis | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
